Proujansky Roy 4
4 · INNOVATE BIOPHARMACEUTICALS, INC. · Filed Dec 7, 2018
Insider Transaction Report
Form 4
Proujansky Roy
Director
Transactions
- Award
Stock Option (Right to Buy)
2018-12-04+50,000→ 50,000 totalExercise: $6.94Exp: 2028-09-21→ Common stock (50,000 underlying) - Award
Stock Option (Right to Buy)
2018-12-04+25,000→ 25,000 totalExercise: $2.41Exp: 2028-12-04→ Common stock (25,000 underlying)
Footnotes (2)
- [F1]Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan (the "Plan") that was approved by the Compensation Committee of the Board of Directors of Innovate Biopharmaceuticals, Inc. (the "Company") on September 21, 2018, subject to stockholder approval of an amendment to the Plan (the "Plan Amendment"). The Company's stockholders approved the Plan Amendment on December 4, 2018. 13,750 of these options vested on September 21, 2018, and 36,250 options vest monthly thereafter over 29 months.
- [F2]Grant to the reporting person of stock options under the Innovate Biopharmaceuticals, Inc. 2012 Omnibus Incentive Plan. These stock options vest in 36 equal monthly installments.